Solriamfetol
- Generic Name
- Solriamfetol
- Brand Names
- Sunosi
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O2
- CAS Number
- 178429-62-4
- Unique Ingredient Identifier
- 939U7C91AI
- Background
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Solriamfetol was given FDA approval in 2019.
- Indication
Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients.
- Associated Conditions
- Daytime Sleepiness
- Associated Therapies
- -
Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 60
- Registration Number
- NCT06590662
- Locations
- 🇫🇷
University Hospital of Montpellier, Montpellier, France
RECOVER-SLEEP: Platform Protocol
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1074
- Registration Number
- NCT06404086
- Locations
- 🇺🇸
University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 474
- Registration Number
- NCT06404099
- Locations
- 🇺🇸
All sites listed under NCT06404086, Durham, North Carolina, United States
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 46
- Registration Number
- NCT06170970
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA)
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Ignis Therapeutics (Suzhou) Limited
- Target Recruit Count
- 204
- Registration Number
- NCT06103825
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, ShangHai, Shanghai, China
🇨🇳Peking University Sixth Hospital, Beijing, China
🇨🇳Hangzhou seventh People's Hospital, Hangzhou, China
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT04789174
- Locations
- 🇺🇸
FutureSearch Trials of Neuroglogy, Austin, Texas, United States
🇳🇱Amphia Hospital, Breda, Netherlands
🇪🇸Instiut de Reccerca Biomedica de Lledia, Lleida, Spain
Solriamfetol in Binge Eating Disorder
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 64
- Registration Number
- NCT04602936
- Locations
- 🇺🇸
Lindner Center of HOPE, Mason, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.